


RealRate


PHARMACEUTICAL 2020

REGENERON PHARMACEUTICALS INC. Rank 17 of 362

REGENERON







The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 420% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Other Assets, reducing the Economic Capital Ratio by 2.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 528% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	7,689,100
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,096,600
Liabilities, Non-Current	905,000
Other Assets	7,116,100
Other Compr. Net Income	33,400
Other Expenses	1,095,500
Other Liabilities	713,900
Other Net Income	219,300
Property and Equipment	0
Research and Development	3,036,600
Revenues	7,863,400
Selling, General and Administrative Expense	1,834,800

Output Variable	Value in 1000 USD
Assets	14,805,200
Liabilities	3,715,500
Expenses	5,966,900
Stockholders Equity	11,089,700
Net Income	2,115,800
Comprehensive Net Income	2,132,500
Economic Capital Ratio	225%

